Tags : Puma Biotechnology

Insights+: Key Events of ASCO 2019

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring. […]Read More

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA

Shots: The P-III NALA Trial involves assessing of Neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with HER2-Positive Metastatic Breast Cancer The P-III NALA Trial demonstrated improvement in PFS by 1% and OS by 4% with safety profile consistent with previous trials Neratinib is an irreversible tyrosine kinase inhibitor, or TKI used for blocking signal […]Read More